Lilly makes medicines that help people live longer, healthier, and more active lives. We at Lilly promise to operate our business with absolute integrity, to earn the trust of all, to set the highest standards for our performance and for the performance of our products, and to demonstrate caring and respect for all those who share in our mission and are touched by our work.
The company conducts business in a highly regulated environment and is committed to market its products responsibly and in a manner that safeguards patients and promotes science & knowledge. The company has global policies, re-affirming its commitment to, and expectations of its employees to, ethical interactions. This includes company expectations regarding the promotion of company medicines and devices.
All employees must act ethically, and comply with all applicable laws, regulations, and industry codes of practice that govern company interactions with external parties, including healthcare providers, government and public officials, and private individuals. Employees must act ethically in both the public and private sector. In fact, Lilly has a long-standing set of internal guidelines (The Red Book) that provides the basis for all employees’ making of ethical decisions across the spectrum of groups, individuals, and scenarios.
To help assure stakeholders that Lilly’s business transactions are with integrity and beyond reproach, Lilly implemented an enhanced anti-corruption and transparency program called Integrity in Business. The program helps to document all business transactions with third parties, partners, and healthcare providers are appropriate, transparent, and legitimate. The overall objective is to be above board on all our business practices.
The Eli Lilly Singapore Pte Ltd’s Integrity in Business Program.
Pharmaceutical companies routinely enter into contracts with physicians and other health care professionals who provide services as consultants, advisory- board participants, and clinical -trial researchers. These types of contracts partnerships are an essential part of doing business and conducting medical research. In recent years however, these relationships have been under increasing scrutiny. To help assure our stakeholders that our business transactions with health care providers are beyond reproach, Lilly Singapore recently implemented an enhanced anti - corruption and transparency program called Integrity in Business.
As part of this program, all business transactions between Lilly and health care providers are first evaluated analyzed and logged, and if appropriate, approved by our Ethics and Compliance Officer - Business Integrity Office. The process helps to document the fact that all business transactions with our third - party physician partners are appropriate and legitimate, and that we are paying a fair- market or reasonable value for these services.
REPORT AN ETHICS VIOLATION / CONCERN:
If you believe that in the course of doing business we have not met regulations, or even fallen short of our own values, please tell us by calling the Lilly Ethics and Compliance Global Hotline at 800-1204201 or via www.lillyethics.ethicspoint.com.
Health, Safety and Environmental Policy
Eli Lilly Singapore follows an internal Health, Safety and the Environment (HS&E) policy aligned with Lilly’s values of respect for people, integrity, and excellence. The purpose of these beliefs was to link our company values to desired expectations, behaviours, and ultimately results that define the performance of Eli Lilly and Company relative to injury prevention and environmental protection.